Skip to search formSkip to main contentSkip to account menu

romiplostim

Known as: Amgen Megakaryopoiesis Protein 2 
A drug used to treat patients with immune thrombocytopenic purpura (ITP) who do not get better with other forms of treatment. In ITP, platelets… 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

AMG531Nplate

Broader (3)

Fc ReceptorRecombinant Fusion ProteinsThrombopoietin
Thrombopoietin Receptor Agonists [MoA]romiplostim 0.25 MG Injection [Nplate]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study
BackgroundThe EMN02/HO95 trial is the largest multicenter, randomized, phase 3 study conducted in the novel agent era and aimed… 
Review
2017
Review
2017
Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion
Vitamin D is recognized to play an essential role in health and disease. In kidney disease, vitamin D analogs have gained… 
2015
2015
Ibandronate Increases Sclerostin Levels and Bone Strength in Male Patients with Idiopathic Osteoporosis
The pathomechanism of male idiopathic osteoporosis (MIO) differs from postmenopausal osteoporosis with regard to alterations in… 
2015
2015
CAR-T field booms as next-generation platforms attract big players
571 upfront and could see $525 million in milestones flowing in each company’s direction— is a high-water mark for CAR-T… 
2014
2014
Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)
Background: Oprozomib (OPZ) is an oral epoxyketone proteasome inhibitor that has shown promising antitumor activity in patients… 
2013
2013
IL-17 antibodies gain momentum
A Phase III trial for a first-in-class psoriasis drug provides encouraging data, but the emerging agents still have to prove… 
Review
2012
Review
2012
Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and…
Abstract 421 [][1] Background: There are few therapies for thrombocytopenia in MDS, which is found in ∼50% of pts with low/int-1… 
Review
2011
Review
2011
Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer
Objective: The objective of this systematic review is to summarize the literature to date on the rates of infusion reactions (IR… 
Review
2009
Review
2009
Romiplostim: a second-generation thrombopoietin agonist.
Thrombopoietin (TPO) is the major regulator of both megakaryopoiesis and platelet production. TPO is a glycoprotein primarily… 
2008
2008
Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia
After many decades of an orphan existence, immune thrombocytopenic purpura is a central focus for the clinical development of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)